Rhythm Pharmaceuticals In... (RYTM)
| Bid | 52 |
| Market Cap | 3.38B |
| Revenue (ttm) | 133.56M |
| Net Income (ttm) | -268.81M |
| EPS (ttm) | -4.34 |
| PE Ratio (ttm) | -12.33 |
| Forward PE | -23.42 |
| Analyst | Buy |
| Ask | 58.94 |
| Volume | 400,800 |
| Avg. Volume (20D) | 514,545 |
| Open | 54.17 |
| Previous Close | 54.30 |
| Day's Range | 53.44 - 55.13 |
| 52-Week Range | 35.17 - 68.58 |
| Beta | 2.30 |
About RYTM
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström sy...
Analyst Forecast
According to 12 analyst ratings, the average rating for RYTM stock is "Buy." The 12-month stock price forecast is $70, which is an increase of 30.79% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
4 weeks ago · seekingalpha.com
Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2024 Earnings Call TranscriptRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q4 2024 Earnings Conference Call February 26, 2025 8:00 AM ET Company Participants David Connolly – Investor Relations and Corporate Communications David Me...
